NCT01043666

A Study of YM178 in Subjects With Symptoms of Overactive Bladder

Phase III Study of YM178: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study in Subjects With Symptoms of Overactive Bladder

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,126 (actual)
• Sponsor: Astellas Pharma Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is to assess the efficacy and safety of YM178 in patients with symptoms of overactive bladder.

Conditions

• Urinary Bladder, Overactive

Interventions

Type	Name	Description
DRUG	YM178	oral
DRUG	Placebo	oral
DRUG	tolterodine ER	oral

Timeline

• Start date: 2009-12-21
• Primary completion: 2011-09-16
• Completion: 2011-09-16
• First posted: 2010-01-07
• Last updated: 2024-10-31

Locations

35 sites across 4 countries: China, India, South Korea, Taiwan